Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial : full-length article
by Voci, Davide (Author)
, Götschi, Andrea (Author)
, Held, Ulrike (Author)
, Bingisser, Roland (Author)
, Colucci, Giuseppe (Author)
, Dürschmied, Daniel (Author)
, Fumagalli, Riccardo M. (Author)
, Gerber, Bernhard (Author)
, Hasse, Barbara (Author)
, Keller, Dagmar I. (Author)
, Konstantinides, Stavros V. (Author)
, Mach, François (Author)
, Rampini, Silvana K. (Author)
, Righini, Marc (Author)
, Robert-Ebadi, Helia (Author)
, Rosemann, Thomas (Author)
, Roth-Zetzsche, Stéphanie (Author)
, Sebastian, Tim (Author)
, Simon, Noemi R. (Author)
, Spirk, David (Author)
, Stortecky, Stefan (Author)
, Vaisnora, Lukas (Author)
, Kucher, Nils (Author)
, Barco, Stefano (Author)
,
Call Number:
Loading…
Located:
Loading…
Article (Journal)
Online Resource